VTGN VistaGen Therapeutics Inc Total Business Assets

VTGN (vistagen.com) - company brandmark

This chart of total assets for Vistagen Therapeutics (VTGN), valued at 52.33, highlights the impact of patent protection for nasal anxiety treatments and strict FDA oversight. Vistagen Therapeutics (VTGN) positions itself as a leading developer of safe, fast-acting neuropreparations. The stability of operational processes is ensured through the use of specialized ancillary medical services for the transport of research samples.

Cumulative Company Assets: Vistagen (VTGN) for 07/04/2022 - 11/01/2026

Analytical breakdowns and data insights for company vistagen.com (VTGN)

- stock quotes and analyst forecast:
Share Price Vistagen|VTGN - Price Target Chart
- market capitalization data:
Market Capitalization VTGN|VTGN - Enterprise Value
- book capitalization information:
Net Asset Value per Share Vistagen|VTGN - Company Net Assets|Market Capitalization to Book Value Ratio vistagen.com|VTGN - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Vistagen Therapeutics|VTGN - Long-Term Debt to Equity|Current Liabilities to Capital Vistagen|VTGN - Company Total Debt|Debt to Book Capitalization Ratio VTGN|VTGN - Company Long-Term Debts|Short-Term Debt Volume Vistagen|Interim Coverage Ratio vistagen.com
- company profitability and valuation multiples indicators:
VTGN - Net Income
Summary company analysis:VistaGen Therapeutics Inc, VTGN
Manufactured products of Vistagen Therapeutics

The lack of a stable cash flow leaves Vistagen Therapeutics (VTGN) vulnerable to external shocks, meaning the business's margin of safety is determined exclusively by the volume of venture capital raised. By analyzing total asset dynamics, calculated reverse through ROA to eliminate quarterly gaps, an investor assesses the real value of resources and liabilities, which allows for the timely detection of risks associated with the accumulation of illiquid assets.

Direct competitors

Total Business Assets BIIB|Aggregate Company Assets Neurocrine Biosciences, Inc.|Total Business Assets RGC (Regencell Bioscience Ltd)|Company Total Assets AXSM|ACAD - Company Assets|Xenon Pharmaceuticals - Cumulative Company Assets|Company Total Assets vikingtherapeutics.com VKTX|SUPN - Aggregate Company Assets|Aggregate Asset Value CPRX (Catalyst Pharma)|Denali Therapeutics Inc (DNLI) - Aggregate Company Assets|Company Assets Harmony Corp (HRMY)|Cumulative Company Assets BHVN|Aggregate Company Assets AMLX|Company Total Assets TRVI|Company Total Asset Base Praxis Precision Medicines Inc|Aggregate Company Assets Anavex Corp AVXL|Company Total Asset Base CeriBell EEG (CBLL)|PRTA: Cumulative Company Assets|Alector, Inc. - Aggregate Business Assets|ANNX: Company Total Assets|Omeros (OMER) - Company Total Assets|NGNE (Neurogene Corp) - Company Total Assets|ACIU - Company Balance Sheet Assets|Company Total Assets VYGR|NMRA - Company Assets|Aggregate Company Assets Scilex SCLX|TVGN: Total Business Assets|ACOG: Cumulative Company Assets|Aggregate Asset Value CGTX (Cognition Therapeutics Inc.)|IKT (Inhibikase Therapeutics) - Cumulative Company Assets|SAVA: Aggregate Business Assets|ASRT (Assertio Holdings) - Company Total Assets|COYA: Aggregate Asset Value|Company Total Assets OVID|ABOS - Company Assets|Aggregate Company Assets CervoMed Inc. CRVO|Aggregate Asset Value ATHE|Clene Nanomedicine - Company Total Assets|PEPG - Company Total Assets|Jupiter Neurosciences (JUNS) - Aggregate Company Assets|Total Asset Value of Company RLMD (Relmada Corp)|ANVS (Annovis Bio, Inc.) - Company Total Assets|Company Assets Grace Tx GRCE|Cumulative Company Assets AIFF (Firefly Neuroscience)|Company Total Assets anewmeds.com (KLTO)|NeuroSense Therapeutics Ltd. - Cumulative Company Assets|Aggregate Business Assets RVPH (Reviva Pharmaceuticals, Inc.)|MetaVia, Inc. - Company Total Assets|Company Total Asset Base neuraxis.com NRXS|HSDT: Company Total Assets|Cumulative Company Assets Passage Bio|Aggregate Company Assets Neuphoria Therapeutics, Inc.|Minerva (NERV) - Company Total Asset Base|Cumulative Company Assets ATHA (Athira Pharma, Inc.)|Aggregate Company Assets ADXN (addextherapeutics.com)|Alzamend Neuro - Cumulative Company Assets|Aggregate Business Assets CYCN (Cyclerion Therapeutics Inc.)|Protagenic - Company Total Assets|Company Balance Sheet Assets Pasithea Therapeutics (KTTA)|cortigent.com (CRGT) - Aggregate Company Assets|Total Business Assets ATXI|Aggregate Company Assets BrainStorm Cell Therapeutics|Total Business Assets CARA (Cara Therapeutics Inc.)|Company Total Assets CHRO|ELYM - Company Assets|Intra-Cellular Therapies, Inc. - Cumulative Company Assets|Company Total Assets longboardpharma.com LBPH|MRNS - Aggregate Company Assets|Aggregate Asset Value NKGN (NKGen Biotech Inc)|NeuroBo (NRBO) - Aggregate Company Assets|Company Assets Sage Therapeutics Inc (SAGE)|Cumulative Company Assets SNPX|Aggregate Company Assets TRVN|Company Total Assets VIGL|Company Total Asset Base anewmeds.com|Aggregate Company Assets Cerevel CERE